Chardan Capital Rates Opus Genetics (IRD) buy, $13 Price Target

Analyst Daniil Gataulin maintained a buy rating on Opus Genetics, Inc. with a $13.00 price target as shares change hands around $3.82, a 239.90% upside from the current price.

By EarningsIQ Research Desk · Published Jun 18, 2026, 1:01 PM EDT · Updated Jun 24, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Chardan Capital rated Opus Genetics, Inc. ($IRD) "buy" with a $13 price target on June 18, 2026.

Since the rating, $IRD is down 8.6% after 1 week, down 25.1% after 1 month and down 5.7% to date (from the $4.07 close on Jun 18, 2026).

IRD Opus Genetics, Inc.

$3.84 +81.13% year to date

Daily close · Oct 16, 2026

Key Points

Chardan Capital analyst Daniil Gataulin reiterated a buy rating on Opus Genetics, Inc. (NasdaqCM: IRD) on June 18, 2026, pointing to a $13.00 price target.
Chardan Capital's $13 price target implies 239.90% upside from Opus Genetics, Inc.'s ($IRD) current $3.82 share price.
The shares trade near $3.82, well below Wall Street targets that span from an $8.00 low to a high of $20.00.
A broader group of firms including Citizens, Jones Trading, and Oppenheimer maintain optimistic views on the biotech developer with targets reaching up to $17.00 and $20.00.

Get $IRD trade alerts by text

We text you when insiders, Congress or big funds trade $IRD. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Opus Genetics, Inc. alert may contain errors. Disclosures

Chardan Capital Stands Behind Its $13.00 Target for Opus Genetics

Chardan Capital analyst Daniil Gataulin reiterated a buy rating on Opus Genetics, Inc. (NasdaqCM: IRD) on June 18, 2026, keeping a $13.00 price target in place. The decision puts a spotlight on the wide gap between where the biotech firm currently trades and where its covering analysts think it could head over the coming months.

Stock Valuation and the Gap to Wall Street Targets

With the shares changing hands around $3.82, the $13.00 target from Chardan Capital implies substantial upside from current market levels. The stock recently bounced between a 52-week low of $1.50 and a 52-week high of $7.07. Its 50-day moving average sits at $4.06, while the 200-day moving average rests near $3.87. Opus Genetics carries a strong buy recommendation key across a wider pool of 17 analysts, whose targets average out to $13.00 with a low of $8.00 and an upper ceiling of $20.00.

12-month forecast

$IRD price target

Opus Genetics, Inc. daily closes and this analyst's $13 target. Not advice.

Analysts Set New Price Targets

Wall Street firms have kept a steady stream of updates flowing for the clinical-stage developer throughout late summer and autumn. On October 16, 2026, Citizens reiterated its market outperform rating and a $17.00 price target. Earlier in the month on October 6, 2026, Jones Trading maintained a buy rating while lifting its target to $17.00 from $10.00. Chardan Capital itself checked in again on October 2, 2026, maintaining a buy rating with a $16.00 target. Back on September 10, 2026, Wedbush maintained an outperform rating and raised its target to $13.00 from $10.00. Oppenheimer also stayed bullish on September 9, 2026, maintaining an outperform rating and pushing its target up to $20.00 from $10.00. HC Wainwright & Co. reiterated a buy rating with an $8.00 target on September 9, 2026, while BTIG kept a buy rating and a $12.00 target on the same day.

Inside the Pipeline at Opus Genetics

Opus Genetics is a Durham, North Carolina-based enterprise working on gene therapies designed to restore vision and prevent blindness for patients dealing with inherited retinal diseases and other ophthalmic conditions. Its pipeline features early-stage clinical programs such as OPGx-LCA5 for LCA5-associated retinal degeneration and OPGx-BEST1 for BEST1-associated retinal disease, alongside several pre-clinical candidates targeting retinitis pigmentosa and retinal dystrophy. The firm employs 27 people and trades under the ticker IRD.

What to Watch Ahead for IRD

Investors tracking Opus Genetics will look toward the company's next financial update scheduled for November 11, 2026, to gauge cash burn and pipeline progress. Analyst coverage will likely remain active as clinical milestones approach for its lead retinal disease programs.